Çѹ̾àÇ°(´ëÇ¥ÀÌ»ç ¿ìÁ¾¼ö·±Ç¼¼Ã¢)Àº Á¦47ȸ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Ãß°èÇмú´ëȸ »êÇм¼¼Ç¿¡¼ ¾Æ¸ðÀßź Æйи®ÀÇ ÀÓ»ó °á°ú¸¦ ¹ßÇ¥Çß´Ù°í 7ÀÏ ¹àÇû´Ù.
|
|
|
¡ã Çѹ̾àÇ°Àº Á¦47ȸ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Ãß°èÇмú´ëȸ »êÇм¼¼Ç¿¡¼ ¾Æ¸ðÀßź Æйи®ÀÇ ÀÓ»ó °á°ú¸¦ ¹ßÇ¥Çß´Ù. |
´ëÇÑ°íÇ÷¾ÐÇÐȸ´Â Áö³ 3ÀÏ ¼¿ï ÄÜ·¡µåÈ£ÅÚ¿¡¼ °³ÃÖµÆÀ¸¸ç ¼¼¼Ç¿¡¼´Â ¾Æ¸ðÀßźÀÇ ±¹³» ÀÓ»ó °á°ú ¿ä¾à°ú ÇÔ²² ¾Æ¸ðÀßźÇ÷¯½º·¾Æ¸ðÀßźťÀÇ 3»ó ÀÓ»ó °á°úµµ ÇÔ²² ¹ßÇ¥µÆ´Ù.
½ÉÆ÷Áö¾öÀÇ ÁÂÀåÀº ¼¿ïÀÇ´ë ±èöȣ ±³¼ö¿Í ´ë±¸°¡Å縯ÀÇ´ë ±è±â½Ä ±³¼ö°¡ ¸Ã¾Ò´Ù. ù ¹ø° ¿¬ÀÚ·Î ³ª¼± °í·ÁÀÇ´ë ±èÀÀÁÖ ±³¼ö´Â ‘Evidence-based approach for intensive BP control’¸¦ ÁÖÁ¦·Î ¹ßÇ¥¸¦ ÁøÇàÇß´Ù.
±è ±³¼ö´Â “Ŭ·Î¸£Å»¸®µ·Àº ´Ù¾çÇÑ ÀÓ»óÀû Áõ°Å¿Í ÇÔ²² ź»êÅ»¼öÈ¿¼Ò ¾ïÁ¦¿Í °°Àº ºÎ°¡ÀûÀÎ È¿°ú¸¦ º¸¿©ÁÖ´Â ±âÁ¸ ÇÏÀ̵å·ÎŬ·Î·ÎƼ¾ÆÁöµå¿Í´Â Â÷º°È µÈ ÀÌ´¢Á¦”¶ó¸ç “Àü ¼¼°èÀûÀ¸·Îµµ Ŭ·Î¸£Å»¸®µ· »ç¿ëÀÌ Áõ°¡ÇÏ´Â Ãß¼¼”¶ó°í ¼³¸íÇß´Ù.
ÀÌ¾î ±è ±³¼ö´Â “Ŭ·Î¸£Å»¸®µ·À» Æ÷ÇÔÇÑ ¾Æ¸ðÀßźÇ÷¯½º´Â °íÇ÷¾ÐÄ¡·á 3Á¦ ¿ä¹ý¿¡¼ º¸´Ù °·ÂÇÑ °¾Ð È¿°ú¿Í ȯÀÚÀÇ º¹¾à ¼øÀÀµµ °³¼±À» ±â´ëÇÒ ¼ö ÀÖÀ» °Í”À̶ó°í ¸»Çß´Ù.
µÎ ¹ø° ¿¬ÀÚ·Î ³ª¼± ÇѸ²ÀÇ´ë ¹Ú¿ìÁ¤ ±³¼ö´Â ‘Towards optimal management of CV risk in hypertensive patients with dyslipidemia’ÀÇ ÁÖÁ¦·Î ¹ßÇ¥Çß´Ù.
¹Ú ±³¼ö´Â “½ºÅ¸Æ¾Àº LDL-C Á¶ÀýÀÇ Çʼö ¾àÁ¦ÀÓ¿¡µµ ºÒ±¸ÇÏ°í ȯÀÚµéÀÇ ¼øÀÀµµ°¡ °íÇ÷¾Ð Ä¡·áÁ¦¿¡ ºñÇØ ¿©ÀüÈ÷ ³·´Ù”¸ç “¾Æ¸ðÀßźť´Â LDL-C Á¶ÀýÀÌ ÇÊ¿äÇÑ ÁßÀúÀ§Çè ȯÀÚ±º¿¡¼ º¹¾à¼øÀÀµµ¸¦ Çâ»ó½ÃÅ°°í ±âÁ¸ ARB/STATIN º¹ÇÕÁ¦ ´ëºñ °·ÂÇÑ ¸ñÇ¥Ç÷¾Ð µµ´ÞÀ» ±â´ëÇÒ ¼ö ÀÖ´Â »õ·Î¿î Ä¡·á ¿É¼Ç”À̶ó°í ¼³¸íÇß´Ù.
Çѹ̾àÇ° ¸¶ÄÉÆûç¾÷ºÎ ¹Ú¸íÈñ »ó¹«ÀÌ»ç´Â “¾Æ¸ðÀßź Æйи®´Â °íÇ÷¾Ð ȯÀÚÀÇ Àû±ØÀûÀÎ ¸ñÇ¥Ç÷¾Ð °ü¸®¸¦ À§ÇÑ ÃÖÀûÀÇ ÆÄÀÌÇÁ¶óÀΔÀ̶ó¸ç “¾Æ¸ðÀßź Æйи®ÀÇ ÀÓ»óÀû ±Ù°Å¸¦ ¾Ë¸± ¼ö ÀÖ´Â ´Ù¾çÇÑ ±âȸ¸¦ ¸¶·ÃÇØ ³ª°¡´Â Àû±ØÀû ¸¶ÄÉÆÃÀ» Áö¼ÓÇÏ°Ú´Ù”°í ¸»Çß´Ù.
ÇÑÆí, 2017³â 9¿ù Ãâ½ÃµÈ ¾Æ¸ðÀßźÇ÷¯½º(Amlodipine/Losartan/Chlorthalidone)¿Í 2017³â 10¿ù Ãâ½ÃµÈ ¾Æ¸ðÀßźť(Amlodipine/Losartan/Rosuvastatin)´Â ±¹³» 3»ó ÀÓ»óÀ» ÅëÇØ ±× À¯È¿¼º°ú ³»¾à¼ºÀ» ÀÔÁõÇÑ ¹Ù ÀÖ´Ù. ¾Æ¸ðÀßźÇ÷¯½ºÀÇ 3»ó ÀÓ»ó ³í¹®Àº SCI±Þ ÇмúÁöÀÎ Clinical Therapeutics¿¡ °ÔÀçµÆÀ¸¸ç ¾Æ¸ðÀßźťÀÇ 3»ó ÀÓ»ó ³í¹® ¿ª½Ã °°Àº ÇмúÁö¿¡ äÅõŠ°ÔÀçµÉ ¿¹Á¤ÀÌ´Ù. < ÀúÀÛ±ÇÀÚ © ¾à±¹½Å¹® ¹«´ÜÀüÀç ¹× Àç¹èÆ÷±ÝÁö > |